NASP
gene geneOn this page
Also known as FLB7527FLJ31599FLJ35510MGC19722MGC20372MGC2297DKFZp547F162PRO1999
Summary
NASP (nuclear autoantigenic sperm protein, HGNC:7644) is a protein-coding gene on chromosome 1p34.1, encoding Nuclear autoantigenic sperm protein (P49321). Component of the histone chaperone network. It is a selective cancer dependency (DepMap: 40.6% of cell lines).
This gene encodes a H1 histone binding protein that is involved in transporting histones into the nucleus of dividing cells. Multiple isoforms are encoded by transcript variants of this gene. The somatic form is expressed in all mitotic cells, is localized to the nucleus, and is coupled to the cell cycle. The testicular form is expressed in embryonic tissues, tumor cells, and the testis. In male germ cells, this protein is localized to the cytoplasm of primary spermatocytes, the nucleus of spermatids, and the periacrosomal region of mature spermatozoa.
Source: NCBI Gene 4678 — RefSeq curated summary.
At a glance
- GWAS associations: 12
- Clinical variants (ClinVar): 130 total
- GTEx eGene: eQTL in 14 tissues, sQTL in 6 (q < 0.05)
- Cancer dependency (DepMap): dependent in 40.6% of screened cell lines
- Constraint (gnomAD): pLI 1.00 (loss-of-function intolerant), LOEUF 0.39 (moderately constrained)
- MANE Select transcript:
NM_002482 - Interaction hub: 1,932 STRING partners (top 8% of genes corpus-wide)
- Notable: 130 clinical variants but no curated precision-oncology (CIViC) evidence yet
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:7644 |
| Approved symbol | NASP |
| Name | nuclear autoantigenic sperm protein |
| Location | 1p34.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLB7527, FLJ31599, FLJ35510, MGC19722, MGC20372, MGC2297, DKFZp547F162, PRO1999 |
| Ensembl gene | ENSG00000132780 |
| Ensembl biotype | protein_coding |
| OMIM | 603185 |
| Entrez | 4678 |
Gene structure
Transcript identifiers
Ensembl transcripts: 84 — 51 protein_coding, 27 nonsense_mediated_decay, 4 retained_intron, 2 protein_coding_CDS_not_defined
MANE Select: ENST00000350030
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 2: 8, TSL 3: 4, TSL 4: 4, TSL 5: 7
ENST00000350030, ENST00000351223, ENST00000372052, ENST00000437362, ENST00000437901, ENST00000453748, ENST00000464190, ENST00000470768, ENST00000472408, ENST00000481782, ENST00000525515, ENST00000527359, ENST00000527470, ENST00000527932, ENST00000528084, ENST00000528238, ENST00000529333, ENST00000530073, ENST00000530840, ENST00000531532, ENST00000531612, ENST00000534101, ENST00000534450, ENST00000537798, ENST00000629893, ENST00000858824, ENST00000858825, ENST00000858826, ENST00000858827, ENST00000858828, ENST00000858829, ENST00000858830, ENST00000923964, ENST00000923965, ENST00000923966, ENST00000923967, ENST00000923968, ENST00000923969, ENST00000923970, ENST00000923971, ENST00000923972, ENST00000923973, ENST00000923974, ENST00000923975, ENST00000923976, ENST00000923977, ENST00000923978, ENST00000923979, ENST00000923980, ENST00000923981, ENST00000961668, ENST00000961669, ENST00000974479, ENST00000974480, ENST00000974481, ENST00001052299, ENST00001052300, ENST00001052301, ENST00001070513, ENST00001070518, ENST00001070531, ENST00001070532, ENST00001070533, ENST00001070534, ENST00001101225, ENST00001101226, ENST00001101227, ENST00001101228, ENST00001101229, ENST00001101230, ENST00001101231, ENST00001101232, ENST00001101233, ENST00001101234, ENST00001101235, ENST00001101236, ENST00001101237, ENST00001101238, ENST00001101239, ENST00001101240, ENST00001101241, ENST00001101242, ENST00001101243, ENST00001145635
RefSeq mRNA: 3 — MANE Select: NM_002482
NM_001195193, NM_002482, NM_152298
CCDS: CCDS524, CCDS525, CCDS55597
Canonical transcript exons
ENST00000350030 — 15 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001815639 | 45618061 | 45618893 |
| ENSE00003470022 | 45604936 | 45605016 |
| ENSE00003478736 | 45615013 | 45615201 |
| ENSE00003487994 | 45606482 | 45606591 |
| ENSE00003490574 | 45584041 | 45584205 |
| ENSE00003511854 | 45591223 | 45591270 |
| ENSE00003512169 | 45616626 | 45616703 |
| ENSE00003548507 | 45613169 | 45613248 |
| ENSE00003568340 | 45614096 | 45614181 |
| ENSE00003586112 | 45607321 | 45608337 |
| ENSE00003595072 | 45615305 | 45615471 |
| ENSE00003614735 | 45614293 | 45614366 |
| ENSE00003672570 | 45617463 | 45617591 |
| ENSE00003677926 | 45616337 | 45616393 |
| ENSE00003680489 | 45602255 | 45602365 |
Expression profiles
Bgee: expression breadth ubiquitous, 292 present calls, max score 99.49.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 42.0967 / max 1408.6541, expressed in 1793 samples.
Highest expression (Bgee): ventricular zone, embryo, ganglionic eminence, oocyte, testis.
Genetic regulation across tissues (GTEx eQTL / sQTL)
NASP is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 14 tissues and its splicing (sQTL) in 6 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
20 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Nerve Tibial | eqtl | 6.6e-07 | +0.13 | 1:45611756:G:C |
| Cells Cultured fibroblasts | eqtl | 1.4e-03 | -0.05 | 1:45698302:T:A |
| Artery Tibial | eqtl | 6.1e-03 | -0.10 | 1:45429219:G:T |
| Artery Aorta | sqtl | 8.7e-03 | +0.95 | 1:45826853:G:A |
| Skin Sun Exposed Lower leg | sqtl | 1.4e-02 | +0.24 | 1:45024221:G:C |
| Brain Cerebellar Hemisphere | eqtl | 1.6e-02 | +0.46 | 1:44681063:C:T |
| Heart Atrial Appendage | eqtl | 2.3e-02 | +0.15 | 1:45567628:T:C |
| Small Intestine Terminal Ileum | eqtl | 2.8e-02 | -0.49 | 1:46488836:AC:A |
| Artery Aorta | eqtl | 3.2e-02 | +0.15 | 1:45571288:T:C |
| Esophagus Muscularis | sqtl | 3.2e-02 | +0.71 | 1:45573343:A:G |
| Esophagus Muscularis | eqtl | 3.3e-02 | -0.22 | 1:46527531:A:G |
| Liver | eqtl | 3.4e-02 | +0.27 | 1:45325482:G:A |
| Skin Not Sun Exposed Suprapubic | sqtl | 3.6e-02 | +0.32 | 1:45557684:A:T |
| Thyroid | eqtl | 3.6e-02 | -0.43 | 1:44672301:A:G |
| Esophagus Gastroesophageal Junction | eqtl | 3.6e-02 | -0.12 | 1:44974313:A:C |
| Whole Blood | eqtl | 4.5e-02 | +0.10 | 1:46138643:G:A |
| Artery Tibial | sqtl | 4.5e-02 | +0.63 | 1:45573343:A:G |
| Brain Putamen basal ganglia | eqtl | 4.7e-02 | +0.56 | 1:44632259:C:T |
| Skin Not Sun Exposed Suprapubic | eqtl | 4.7e-02 | -0.31 | 1:46333550:A:G |
| Muscle Skeletal | sqtl | 5.0e-02 | +0.20 | 1:45666201:T:C |
FANTOM5 promoters
2 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 2695 | 42.0038 | 1793 |
| 201498 | 0.0929 | 28 |
Top tissues by expression
showing 100 of 295 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| ventricular zone | UBERON:0003053 | 99.49 | gold quality |
| embryo | UBERON:0000922 | 99.35 | gold quality |
| ganglionic eminence | UBERON:0004023 | 99.27 | gold quality |
| oocyte | CL:0000023 | 99.08 | gold quality |
| right testis | UBERON:0004534 | 98.78 | gold quality |
| left testis | UBERON:0004533 | 98.67 | gold quality |
| secondary oocyte | CL:0000655 | 98.60 | gold quality |
| sural nerve | UBERON:0015488 | 98.56 | gold quality |
| cortical plate | UBERON:0005343 | 98.16 | gold quality |
| right ovary | UBERON:0002118 | 98.03 | gold quality |
| left ovary | UBERON:0002119 | 97.97 | gold quality |
| testis | UBERON:0000473 | 97.96 | gold quality |
| right uterine tube | UBERON:0001302 | 97.77 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 97.74 | gold quality |
| body of uterus | UBERON:0009853 | 97.69 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 97.68 | gold quality |
| colonic epithelium | UBERON:0000397 | 97.67 | gold quality |
| corpus callosum | UBERON:0002336 | 97.64 | gold quality |
| lymph node | UBERON:0000029 | 97.48 | gold quality |
| endocervix | UBERON:0000458 | 97.44 | gold quality |
| spleen | UBERON:0002106 | 97.37 | gold quality |
| left uterine tube | UBERON:0001303 | 97.34 | gold quality |
| ectocervix | UBERON:0012249 | 97.29 | gold quality |
| ovary | UBERON:0000992 | 97.24 | gold quality |
| rectum | UBERON:0001052 | 97.21 | gold quality |
| spinal cord | UBERON:0002240 | 97.18 | gold quality |
| vermiform appendix | UBERON:0001154 | 97.15 | gold quality |
| tibial nerve | UBERON:0001323 | 97.13 | gold quality |
| peritoneum | UBERON:0002358 | 97.07 | gold quality |
| omental fat pad | UBERON:0010414 | 97.07 | gold quality |
| calcaneal tendon | UBERON:0003701 | 97.06 | gold quality |
| caecum | UBERON:0001153 | 96.94 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 96.93 | gold quality |
| endometrium | UBERON:0001295 | 96.89 | gold quality |
| mucosa of stomach | UBERON:0001199 | 96.81 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 96.81 | gold quality |
| thymus | UBERON:0002370 | 96.80 | gold quality |
| cerebellar cortex | UBERON:0002129 | 96.75 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 96.72 | gold quality |
| tendon of biceps brachii | UBERON:0008188 | 96.71 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 96.70 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 96.68 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 96.67 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 96.67 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 96.65 | gold quality |
| adipose tissue of abdominal region | UBERON:0007808 | 96.64 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 96.62 | gold quality |
| adenohypophysis | UBERON:0002196 | 96.60 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 96.58 | gold quality |
| right lung | UBERON:0002167 | 96.50 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 96.49 | gold quality |
| tonsil | UBERON:0002372 | 96.47 | gold quality |
| middle frontal gyrus | UBERON:0002702 | 96.44 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 96.43 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 96.42 | gold quality |
| lower esophagus | UBERON:0013473 | 96.41 | gold quality |
| metanephros cortex | UBERON:0010533 | 96.40 | gold quality |
| minor salivary gland | UBERON:0001830 | 96.37 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 96.35 | gold quality |
| uterus | UBERON:0000995 | 96.34 | gold quality |
| thyroid gland | UBERON:0002046 | 96.31 | gold quality |
| right atrium auricular region | UBERON:0006631 | 96.28 | gold quality |
| bone marrow | UBERON:0002371 | 96.23 | gold quality |
| vagina | UBERON:0000996 | 96.21 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 96.19 | gold quality |
| cerebellum | UBERON:0002037 | 96.12 | gold quality |
| esophagus | UBERON:0001043 | 96.10 | gold quality |
| upper lobe of lung | UBERON:0008948 | 96.10 | gold quality |
| transverse colon | UBERON:0001157 | 96.07 | gold quality |
| female reproductive system | UBERON:0000474 | 96.04 | gold quality |
| tendon | UBERON:0000043 | 96.00 | gold quality |
| amygdala | UBERON:0001876 | 96.00 | gold quality |
| small intestine | UBERON:0002108 | 95.95 | gold quality |
| skin of abdomen | UBERON:0001416 | 95.93 | gold quality |
| inferior vagus X ganglion | UBERON:0005363 | 95.90 | gold quality |
| bone marrow cell | CL:0002092 | 95.89 | gold quality |
| body of stomach | UBERON:0001161 | 95.89 | gold quality |
| subcutaneous adipose tissue | UBERON:0002190 | 95.87 | gold quality |
| esophagus mucosa | UBERON:0002469 | 95.84 | gold quality |
| gall bladder | UBERON:0002110 | 95.83 | gold quality |
| pituitary gland | UBERON:0000007 | 95.80 | gold quality |
| right frontal lobe | UBERON:0002810 | 95.76 | gold quality |
| fundus of stomach | UBERON:0001160 | 95.66 | gold quality |
| stomach | UBERON:0000945 | 95.59 | gold quality |
| tibial artery | UBERON:0007610 | 95.59 | gold quality |
| popliteal artery | UBERON:0002250 | 95.58 | gold quality |
| myometrium | UBERON:0001296 | 95.57 | gold quality |
| mouth mucosa | UBERON:0003729 | 95.56 | gold quality |
| left coronary artery | UBERON:0001626 | 95.52 | gold quality |
| intestine | UBERON:0000160 | 95.47 | gold quality |
| sigmoid colon | UBERON:0001159 | 95.46 | gold quality |
| aorta | UBERON:0000947 | 95.44 | gold quality |
| body of pancreas | UBERON:0001150 | 95.43 | gold quality |
| coronary artery | UBERON:0001621 | 95.43 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 95.35 | gold quality |
| colon | UBERON:0001155 | 95.35 | gold quality |
| apex of heart | UBERON:0002098 | 95.35 | gold quality |
| right lobe of liver | UBERON:0001114 | 95.34 | gold quality |
| large intestine | UBERON:0000059 | 95.30 | gold quality |
| thoracic aorta | UBERON:0001515 | 95.27 | gold quality |
Single-cell (SCXA)
Detected in 16 experiment(s), a significant marker in 12.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-7051 | yes | 957.81 |
| E-HCAD-4 | yes | 42.05 |
| E-HCAD-5 | yes | 40.72 |
| E-CURD-112 | yes | 39.59 |
| E-HCAD-10 | yes | 34.43 |
| E-CURD-122 | yes | 22.58 |
| E-GEOD-125970 | yes | 21.21 |
| E-HCAD-1 | yes | 17.90 |
| E-MTAB-6678 | yes | 7.88 |
| E-MTAB-10553 | yes | 7.81 |
| E-MTAB-9801 | yes | 5.82 |
| E-GEOD-75140 | no | 1970.93 |
| E-MTAB-11121 | no | 864.30 |
| E-MTAB-7008 | no | 807.80 |
| E-MTAB-10137 | no | 6.75 |
HPA expression
RNA tissue specificity: Low tissue specificity
showing 60 of 80 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM | Protein (IHC) |
|---|---|---|---|
| Bone marrow | tissue | 155.7 | medium |
| Thymus | tissue | 93.9 | |
| Tonsil | tissue | 91.4 | high |
| Lymph node | tissue | 85.5 | medium |
| Testis | tissue | 75.6 | high |
| Placenta | tissue | 58.2 | medium |
| Vagina | tissue | 54.3 | medium |
| Appendix | tissue | 52.7 | high |
| Rectum | tissue | 48.3 | high |
| Ovary | tissue | 45.5 | low |
| Colon | tissue | 45.3 | high |
| Spleen | tissue | 43.6 | low |
| Endometrium 1 | tissue | 43.5 | medium |
| Liver | tissue | 42.9 | low |
| Smooth muscle | tissue | 42.2 | low |
| Adipose tissue | tissue | 41.1 | not detected |
| Seminal vesicle | tissue | 40.9 | medium |
| Pituitary gland | tissue | 40.3 | |
| Parathyroid gland | tissue | 38.6 | medium |
| Cervix | tissue | 37.8 | medium |
| Small intestine | tissue | 37.4 | high |
| Fallopian tube | tissue | 37.1 | high |
| Breast | tissue | 35.7 | low |
| Retina | tissue | 35.5 | |
| Urinary bladder | tissue | 35.3 | medium |
| Lung | tissue | 33.7 | high |
| Duodenum | tissue | 32.6 | high |
| Skin 1 | tissue | 31.3 | high |
| Adrenal gland | tissue | 29.9 | low |
| Prostate | tissue | 29.3 | low |
| Stomach 1 | tissue | 28.4 | medium |
| Epididymis | tissue | 28.3 | low |
| Salivary gland | tissue | 27.8 | low |
| Kidney | tissue | 25.9 | low |
| Heart muscle | tissue | 25.6 | low |
| Esophagus | tissue | 25.6 | high |
| Gallbladder | tissue | 25.0 | low |
| Thyroid gland | tissue | 24.2 | low |
| Cerebellum | tissue | 23.1 | low |
| Choroid plexus | tissue | 21.4 | |
| Pancreas | tissue | 21.3 | low |
| Tongue | tissue | 20.8 | |
| Skeletal muscle | tissue | 20.3 | low |
| Postcentral gyrus | tissue | 18.9 | |
| Corpus callosum | tissue | 17.4 | |
| Hippocampus | tissue | 17.0 | low |
| Locus coeruleus | tissue | 16.9 | |
| Olfactory bulb | tissue | 16.9 | |
| Hippocampal formation | tissue | 14.6 | |
| Nucleus accumbens | tissue | 14.4 | |
| Spinal cord | tissue | 14.4 | |
| Amygdala | tissue | 14.3 | |
| Prefrontal cortex | tissue | 13.8 | |
| Cerebral cortex | tissue | 13.8 | low |
| Entorhinal cortex | tissue | 13.8 | |
| Somatosensory cortex | tissue | 13.7 | |
| Midbrain | tissue | 13.6 | |
| Occipital cortex | tissue | 13.6 | |
| Hypothalamus | tissue | 13.5 | |
| Substantia nigra | tissue | 13.4 |
Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Blood vessel (47.9), Paraventricular nucleus (43.7), Nucleus gracilis (38.1), Temporal white matter (37.5), Area striata (white matter) (36.2).
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): E2F4, SP1
miRNA regulators (miRDB)
Targeting NASP by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).
showing 30 of 55 miRNAs:
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-LET-7A-3P | 100.00 | 74.03 | 3932 |
| HSA-LET-7B-3P | 100.00 | 74.08 | 3913 |
| HSA-LET-7F-1-3P | 100.00 | 74.02 | 3928 |
| HSA-MIR-98-3P | 100.00 | 74.08 | 3907 |
| HSA-MIR-29A-3P | 100.00 | 73.11 | 1835 |
| HSA-MIR-29B-3P | 100.00 | 73.18 | 1833 |
| HSA-MIR-29C-3P | 100.00 | 73.15 | 1833 |
| HSA-MIR-1277-5P | 100.00 | 73.95 | 5056 |
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-186-5P | 99.99 | 70.83 | 3707 |
| HSA-MIR-1185-1-3P | 99.98 | 71.04 | 2593 |
| HSA-MIR-1185-2-3P | 99.98 | 71.04 | 2593 |
| HSA-LET-7F-2-3P | 99.98 | 70.98 | 2588 |
| HSA-MIR-4789-5P | 99.98 | 70.76 | 2721 |
| HSA-MIR-3658 | 99.96 | 73.87 | 4379 |
| HSA-MIR-4666A-3P | 99.96 | 71.71 | 3434 |
| HSA-MIR-570-3P | 99.96 | 72.41 | 4910 |
| HSA-MIR-548AA | 99.96 | 70.64 | 3753 |
| HSA-MIR-548AP-3P | 99.96 | 70.64 | 3753 |
| HSA-MIR-548T-3P | 99.96 | 70.64 | 3753 |
| HSA-MIR-381-3P | 99.93 | 71.87 | 2854 |
| HSA-MIR-300 | 99.92 | 71.76 | 2856 |
| HSA-MIR-4493 | 99.90 | 66.48 | 977 |
| HSA-MIR-5682 | 99.89 | 72.56 | 1005 |
| HSA-MIR-3065-3P | 99.87 | 70.25 | 1407 |
| HSA-MIR-544A | 99.84 | 68.66 | 1965 |
| HSA-MIR-323A-3P | 99.79 | 70.30 | 1739 |
| HSA-MIR-1273H-5P | 99.77 | 66.32 | 2471 |
| HSA-MIR-623 | 99.76 | 68.16 | 1170 |
| HSA-MIR-1284 | 99.67 | 73.56 | 1353 |
Functional genomics
gnomAD constraint: pLI 1, LOEUF 0.394, missense Z 0.926 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD
Regional missense constraint (gnomAD)
ENST00000350030 splits into 5 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD
| Region (GRCh38) | Missense obs / exp | o/e | Constrained |
|---|---|---|---|
| 1:45,584,147–45,602,340 | 89 / 79.2 | 1.12 | no |
| 1:45,602,341–45,606,482 | 17 / 38.6 | 0.44 | no |
| 1:45,606,483–45,614,109 | 464 / 469.4 | 0.99 | no |
| 1:45,614,110–45,615,165 | 60 / 114.6 | 0.52 | no |
| 1:45,615,166–45,618,138 | 218 / 219.6 | 0.99 | no |
| DepMap (CRISPR cell-line fitness): dependent in 40.6% of screened cell lines. |
Most-dependent cell lines (DepMap gene-effect, lower = stronger; ≤ −0.5 shown): HPAF-II (-1.412), KP-N-YN (-1.409), NCI-H2126 (-1.114), Evsa-T (-1.094), CHP-212 (-1.075), NCI-H226 (-1.071), NCI-H460 (-1.011), SF126 (-0.991), TYK-nu (-0.99), LS513 (-0.982), KE-97 (-0.981), S-117 (-0.967), PA-TU-8988S (-0.959), HARA (-0.956), HCC515 (-0.949).
Literature-anchored findings (GeneRIF, showing 22)
- NASP and the linker histones are key players in the assembly of chromatin after DNA replication (PMID:16728391)
- NASP forms distinct, high specificity complexes with histones H3 and H4. (PMID:18782834)
- NASP belongs to a network of genes and gene functions that are critical for cell survival (PMID:19439102)
- NASP and RCAS1 proteins were more frequently expressed in ovarian cancer tissues than with normal ovarian tissue and serous cystadenomas and MRE11 was less frequently expressed (PMID:20164540)
- A deletion analysis of sNASP revealed that the central region, amino acid residues 26-325, of sNASP is responsible for nucleosome assembly in vitro. (PMID:20167597)
- tNASP is critical for the survival of prostate cancer cells; targeting tNASP expression can lead to a new approach for prostate cancer treatment. (PMID:21496299)
- sNASP interacts with linker and core histones through distinct structural domains. (PMID:21965532)
- an increase of miR-29a, and hence decrease of Nasp, may contribute to inhibit cell proliferation during postnatal organ development. (PMID:22194605)
- The insights into NASP function and the existence of a tunable reservoir in mammalian cells demonstrate that contingency is integrated into the histone supply chain to respond to unexpected changes in demand. (PMID:22195965)
- Studies indicate that histone chalerones nucleoplasmin (NPM2/NPM3) preferentially associated with histones H2A-H2B in the egg and the nuclear autoantigenic sperm protein (NASP) families. (PMID:22968912)
- NASP family Proteins are highly conserved throughout the eukaryotes and posses four TPR motifs. It was likely present in the last common ancestor of eukaryotes possibly representing an important innovation regarding H3/H4 transport mechanism. Different TPR motifs in NASP have evolved at different rates with TPR1/4 evolving faster than TPR2/3. (PMID:24951090)
- These results provide evidence that tNASP is ubiquitously produced in various types of human tissues and promotes in vitro nucleosome assembly with H3 variant specificity. (PMID:25615412)
- Our research demonstrates that knockdown of tNASP effectively inhibits the proliferation and causes G1 phase arrest through ERK/MAPK signal pathway. (PMID:25669170)
- findings reveal a new mode of interaction between a TPR repeat domain of histone chaperone sNASP and an evolutionarily conserved peptide motif found in canonical H3 and in all histone H3 variants (PMID:26673727)
- NASP is targeted by miR-29c in gastric cancer cells. miR-29c can decrease NASP expression and the effects observed following miR-29c overexpression are partially due to NASP depletion. (PMID:28173777)
- Results found that NASP expression levels were upregulated in liver tumors. Its down-regulation inhibited liver cells from forming tumors. Also, NASP depletion led to a global decrease of histone H3K9me1 modification associated with newly H3 processing, which occurred directly at the promoters of up-regulated anti-tumor genes BACH2 and RunX1T1. (PMID:30076957)
- miR-381-3p targeted and suppressed NASP gene, reduced the viability, migration, invasion, EMT of HNSCC cells, demonstrating that miR-381-3p has the potential to be a therapeutic target in inhibiting the progression of HNSCC (PMID:31797734)
- Knockdown of long noncoding RNA colorectal neoplasia differentially expressed inhibits hepatocellular carcinoma progression by mediating the expression of nuclear autoantigenic sperm protein. (PMID:34633056)
- UBR7 acts as a histone chaperone for post-nucleosomal histone H3. (PMID:34786730)
- Home Dust Mites Promote MUC5AC Hyper-Expression by Modulating the sNASP/TRAF6 Axis in the Airway Epithelium. (PMID:36012669)
- NASP gene contributes to autism by epigenetic dysregulation of neural and immune pathways. (PMID:38443156)
- Nuclear autoantigenic sperm protein facilitates glioblastoma progression and radioresistance by regulating the ANXA2/STAT3 axis. (PMID:38605477)
Cross-species orthologs
5 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | nasp | ENSDARG00000039208 |
| mus_musculus | Nasp | ENSMUSG00000028693 |
| rattus_norvegicus | Nasp | ENSRNOG00000016454 |
| drosophila_melanogaster | Nasp | FBGN0037624 |
| caenorhabditis_elegans | WBGENE00007500 |
Mouse-model phenotypes
Observed phenotypes of the mouse ortholog (MGI:1355328) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 3 distinct phenotype terms.
| Mouse phenotype (MP) | Records |
|---|---|
| decreased embryo size | 1 |
| embryonic growth arrest | 1 |
| embryonic lethality before implantation, complete penetrance | 1 |
Additional cross-species homologs
Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.
| Organism | UniProt | Identity | Method |
|---|---|---|---|
| Bos taurus | Q2T9P4 | 84.7% | Diamond |
| Oryctolagus cuniculus | P27123 | 80.2% | Diamond |
| Xenopus laevis | P06180 | 60.9% | Diamond |
| Halocynthia roretzi | Q02508 | 43.2% | Diamond |
| Schizosaccharomyces pombe 972h- | Q9USQ4 | 32.6% | Diamond |
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| AKR1A1 | protein-coding | 10327 |
| CCDC163 | protein-coding | 126661 |
| MMACHC | protein-coding | 25974 |
| PRDX1 | protein-coding | 5052 |
| CCDC17 | protein-coding | 149483 |
| GPBP1L1 | protein-coding | 60313 |
| IPP | protein-coding | 3652 |
| TMEM69 | protein-coding | 51249 |
Protein
Protein identifiers
Nuclear autoantigenic sperm protein — P49321 (reviewed: P49321)
All UniProt accessions (14): E9PAU3, E9PI86, E9PJQ2, E9PKR5, E9PNB5, E9PPQ8, E9PPR5, E9PQG5, E9PRH9, P49321, H0YDS9, H0YF33, Q5T624, Q5T626
UniProt curated annotations — full annotation on UniProt →
Function. Component of the histone chaperone network. Binds and stabilizes histone H3-H4 not bound to chromatin to maintain a soluble reservoir and modulate degradation by chaperone-mediated autophagy. Required for DNA replication, normal cell cycle progression and cell proliferation. Forms a cytoplasmic complex with HSP90 and H1 linker histones and stimulates HSP90 ATPase activity. NASP and H1 histone are subsequently released from the complex and translocate to the nucleus where the histone is released for binding to DNA. Stabilizes soluble histone H3-H4. Stabilizes soluble histone H3-H4.
Subunit / interactions. Binds to linker H1 histones. Interacts with histones H2A, H2B, H3 and H4. Interacts with histone H3.3. Interacts with histones H3 and H4; NASP is a histone chaperone that stabilizes and maintains a soluble pool of histone H3-H4 dimers. Interacts with ASF1A and ASF1B; the interaction is probably indirect and mediated by H3-H4. Also binds to HSP90 in the cytoplasm; this interaction stimulates binding of NASP to H1-6/H1T.
Subcellular location. Cytoplasm. Nucleus.
Tissue specificity. Isoform 1 is testis- and sperm-specific.
Similarity. Belongs to the NASP family.
Isoforms (4)
| UniProt ID | Names | Canonical? |
|---|---|---|
| P49321-1 | 1, Testicular NASP, tNASP | yes |
| P49321-2 | 2, Somatic NASP, sNASP | |
| P49321-3 | 3 | |
| P49321-4 | 4 |
RefSeq proteins (3): NP_001182122, NP_002473, NP_689511 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR011990 | TPR-like_helical_dom_sf | Homologous_superfamily |
| IPR019544 | Tetratricopeptide_SHNi-TPR_dom | Domain |
| IPR019734 | TPR_rpt | Repeat |
| IPR051730 | NASP-like | Family |
Pfam: PF10516, PF13181
UniProt features (73 total): modified residue 34, compositionally biased region 7, sequence conflict 7, helix 7, region of interest 6, repeat 3, splice variant 3, initiator methionine 1, chain 1, coiled-coil region 1, short sequence motif 1, cross-link 1, sequence variant 1
Structure
Experimental structures (PDB)
5 structures by resolution:
| PDB | Title | Method | Resolution (Å) |
|---|---|---|---|
| 7V1M | Structural basis for the co-chaperone relationship of sNASP and ASF1b | X-RAY DIFFRACTION | 2.83 |
| 7V1L | Structure of sNASP core in complex with H3 alpha3 helix peptide | X-RAY DIFFRACTION | 2.85 |
| 7V6P | Crystal structure of human sNASP TPR domain | X-RAY DIFFRACTION | 2.9 |
| 7V6Q | Crystal structure of sNASP-ASF1A-H3.1-H4 complex | X-RAY DIFFRACTION | 3 |
| 7V1K | Apo structure of sNASP core | X-RAY DIFFRACTION | 3.29 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P49321-F1 | 58.07 | 0.27 |
Human Protein Atlas
Protein class: Predicted intracellular proteins, Plasma proteins, Essential proteins
Protein evidence: Evidence at protein level
Subcellular location (HPA, imaging): nucleoplasm
Antibody reliability (HPA): IH enhanced · IF enhanced
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (35)
| Type | Positions |
|---|---|
| N-acetylalanine | 2 |
| N6-acetyllysine | 33, 243, 288 |
| Phosphothreonine | 123, 170, 390, 464, 477, 490, 683, 138 |
| Phosphoserine | 127, 176, 189, 191, 244, 299, 321, 397, 408, 421, 451, 480, 497, 503, 662, 705, 706, 726, 745, 751, 756, 141 |
| Glycyl lysine isopeptide (lys-gly) (interchain with g-cter in sumo1) | 736 |
Function
Pathways and Gene Ontology
Reactome pathways
0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
MSigDB gene sets: 371 (showing top):
TGGTGCT_MIR29A_MIR29B_MIR29C, E2F_Q4, GOBP_CHROMOSOME_ORGANIZATION, MORF_DNMT1, E2F_Q4_01, GNF2_MSH2, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, MORF_SMC1L1, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, E2F4DP1_01, BROWNE_HCMV_INFECTION_8HR_UP, FISCHER_G1_S_CELL_CYCLE, CROONQUIST_NRAS_SIGNALING_DN, GCM_NPM1
GO Biological Process (8): blastocyst development (GO:0001824), DNA replication (GO:0006260), nucleosome assembly (GO:0006334), DNA replication-dependent chromatin assembly (GO:0006335), male gonad development (GO:0008584), protein transport (GO:0015031), response to testosterone (GO:0033574), CENP-A containing chromatin assembly (GO:0034080)
GO Molecular Function (3): histone binding (GO:0042393), protein-containing complex binding (GO:0044877), protein binding (GO:0005515)
GO Cellular Component (5): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), protein-containing complex (GO:0032991)
GO top-level categories
24 GO namespaces:
| Category | Terms |
|---|---|
| chromatin organization | 3 |
| cellular anatomical structure | 3 |
| binding | 2 |
| in utero embryonic development | 1 |
| animal gross anatomical part developmental process | 1 |
| DNA metabolic process | 1 |
| DNA biosynthetic process | 1 |
| nucleosome organization | 1 |
| protein-DNA complex assembly | 1 |
| gonad development | 1 |
| development of primary male sexual characteristics | 1 |
| transport | 1 |
| intracellular protein localization | 1 |
| establishment of protein localization | 1 |
| response to lipid | 1 |
| response to ketone | 1 |
| kinetochore assembly | 1 |
| protein localization to CENP-A containing chromatin | 1 |
| protein binding | 1 |
| chromosome | 1 |
| intracellular membrane-bounded organelle | 1 |
| nuclear lumen | 1 |
| intracellular anatomical structure | 1 |
| cellular_component | 1 |
Experimentally-supported GO annotations
GO terms backed by direct experimental evidence (ECO experimental codes) — 6 of 16 annotations. The rest are phylogenetic / computational / electronic (IEA).
6 experimentally-supported GO terms:
| GO term | NS | Evidence |
|---|---|---|
| nucleosome assembly | BP | direct assay |
| chromatin | CC | direct assay |
| nucleoplasm | CC | direct assay |
| protein-containing complex | CC | direct assay |
| histone binding | MF | direct assay |
| protein-containing complex binding | MF | direct assay |
Protein interactions and networks
STRING
showing 15 of 1,932 interactions by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| NASP | SLBP | Q14493 | 911 |
| NASP | H1-6 | P22492 | 798 |
| NASP | MYCBP2 | O75592 | 759 |
| NASP | IPO4 | Q8TEX9 | 638 |
| NASP | HAT1 | O14929 | 625 |
| NASP | ASF1A | Q9Y294 | 610 |
| NASP | ASF1B | Q9NVP2 | 609 |
| NASP | UBR7 | Q8N806 | 591 |
| NASP | RBBP7 | Q16576 | 556 |
| NASP | CHAF1B | Q13112 | 554 |
| NASP | RCC1 | P18754 | 549 |
| NASP | GAS2L3 | Q86XJ1 | 535 |
| NASP | MCM4 | P33991 | 526 |
| NASP | GINS2 | Q9Y248 | 525 |
| NASP | WDR76 | Q9H967 | 523 |
IntAct
Human interaction partners of NASP in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
27 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| H3C1 | physical association | 0.910 | 3 |
| H4C16 | association | 0.530 | 1 |
| HAT1 | association | 0.530 | 1 |
| TERF2IP | physical association | 0.510 | 2 |
| FXR2 | physical association | 0.370 | 1 |
| H3-5 | physical association | 0.370 | 1 |
| H3C13 | physical association | 0.370 | 1 |
| HDAC6 | physical association | 0.370 | 1 |
| PTK2 | physical association | 0.370 | 1 |
| TERF2 | physical association | 0.370 | 1 |
| DONSON | association | 0.350 | 1 |
| ARF6 | physical association | 0.000 | 1 |
| BCAR3 | physical association | 0.000 | 1 |
| FTSJ1 | physical association | 0.000 | 1 |
| GABARAPL2 | physical association | 0.000 | 1 |
| HLA-B | physical association | 0.000 | 1 |
| IKBKE | physical association | 0.000 | 1 |
| ITSN1 | physical association | 0.000 | 1 |
| LUC7L2 | physical association | 0.000 | 1 |
| MCC | physical association | 0.000 | 1 |
| MTNR1A | physical association | 0.000 | 1 |
| SGK1 | physical association | 0.000 | 1 |
| STXBP1 | physical association | 0.000 | 1 |
| TFE3 | physical association | 0.000 | 1 |
| TIAM1 | physical association | 0.000 | 1 |
| TRAF6 | physical association | 0.000 | 1 |
| ULK2 | physical association | 0.000 | 1 |
BioGRID (317 interactions; top human partners by supporting records): HIST1H3A (Proximity Label-MS; 13 records), ASF1A (Affinity Capture-MS; 10 records), H3F3A (Co-fractionation; 7 records), HIST1H3E (Co-purification; 6 records), ASF1B (Affinity Capture-MS; 5 records), HIST1H4A (Affinity Capture-MS; 5 records), RBBP4 (Affinity Capture-MS; 5 records), H3F3B (Two-hybrid; 4 records), HAT1 (Affinity Capture-MS; 4 records), HIST1H3H (Two-hybrid; 4 records), AIMP1 (Cross-Linking-MS (XL-MS); 3 records), HIST1H3C (Two-hybrid; 3 records), HIST1H3F (Two-hybrid; 3 records), HIST1H3G (Two-hybrid; 3 records), HIST2H3A (Affinity Capture-MS; 3 records)
SIGNOR signaling
2 signaling interactions:
| A | Effect | B | Mechanism |
|---|---|---|---|
| CSNK2A1 | “down-regulates activity” | NASP | phosphorylation |
| NASP | “down-regulates activity” | TRAF6 | binding |
Protein complexes (CORUM) (3)
Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).
3 complexes by size:
| Complex | Subunits | Members |
|---|---|---|
| Histone H3.1 complex | 10 | CHAF1B, IPO4, ASF1A, ASF1B, CHAF1A, H3C1, H4C1, HAT1, NASP, RBBP4 |
| Histone H3.3 complex | 9 | ASF1A, HIRA, IPO4, NASP, ASF1B, H3-3A, H4C1, HAT1, RBBP4 |
| ASF1-histone containing complex | 7 | ASF1A, ASF1B, CHAF1B, CHEK2, H3C1, NASP, ST13 |
Disease & clinical
Genetic variants
Variant evidence for NASP: 130 ClinVar records (0 pathogenic / likely pathogenic); 12 GWAS associations.
ClinVar
130 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 88 |
| Likely benign | 12 |
| Benign | 1 |
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 36 predictions of 1,305):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| 1:45591271–45591272 | donor_loss | 1.0000 | 5 |
| 1:45602366–45602367 | donor_loss | 1.0000 | 5 |
| 1:45604934–45604935 | acceptor_loss | 1.0000 | 4 |
| 1:45605017–45605018 | donor_loss | 1.0000 | 5 |
| 1:45606480 | acceptor_loss | 1.0000 | 2 |
| 1:45613167 | acceptor_loss | 1.0000 | 3 |
| 1:45613249–45613250 | donor_loss | 1.0000 | 5 |
| 1:45614082 | acceptor_gain | 1.0000 | |
| 1:45615007 | acceptor_gain | 1.0000 | |
| 1:45615011–45615012 | acceptor_loss | 1.0000 | 5 |
AlphaMissense
1,067 missense substitutions predicted likely pathogenic (of 5,148 scored), across 244 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:
| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
|---|---|---|---|
| D655 | 8 | 0.968 | 0.994 |
| F66 | 8 | 0.956 | 0.996 |
| M521 | 8 | 0.933 | 0.988 |
| H714 | 8 | 0.883 | 0.965 |
| D523 | 8 | 0.859 | 0.976 |
| N557 | 8 | 0.838 | 0.971 |
| W519 | 7 | 0.998 | 1.000 |
| E554 | 7 | 0.988 | 0.996 |
| E102 | 7 | 0.985 | 0.998 |
| F529 | 7 | 0.982 | 0.992 |
| F565 | 7 | 0.982 | 0.997 |
| F607 | 7 | 0.979 | 0.996 |
| C84 | 7 | 0.972 | 0.998 |
| E550 | 7 | 0.971 | 0.984 |
| F88 | 7 | 0.966 | 0.990 |
| E97 | 7 | 0.965 | 0.994 |
| D711 | 7 | 0.962 | 0.978 |
| F89 | 7 | 0.955 | 0.989 |
| C568 | 7 | 0.950 | 0.999 |
| R720 | 7 | 0.937 | 0.997 |
HPA cancer prognostics
RNA cancer specificity: Cancer enhanced (Testicular Germ Cell Tumor)
Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.
1 prognostic cancer types:
| Cancer | Prognostic | p-value |
|---|---|---|
| Liver Hepatocellular Carcinoma (TCGA) | unfavorable | 5.02e-07 |
Disease associations
OMIM: gene MIM:603185 | disease phenotypes:
GWAS associations
12 associations:
| Study | Trait | p-value |
|---|---|---|
| GCST010083_244 | Hemoglobin levels | 6e-24 |
| GCST004604_13 | Hematocrit | 3e-14 |
| GCST010702_139 | Subcortical volume (MOSTest) | 4e-14 |
| GCST010703_210 | Brain morphology (MOSTest) | 2e-13 |
| GCST004615_48 | Hemoglobin concentration | 3e-13 |
| GCST010700_23 | Cortical thickness (MOSTest) | 1e-10 |
| GCST005951_47 | Body mass index | 8e-10 |
| GCST010697_3 | Cortical surface area (min-P) | 2e-8 |
| GCST010701_128 | Cortical surface area (MOSTest) | 2e-8 |
| GCST010696_21 | Cortical thickness (min-P) | 3e-8 |
| GCST010698_61 | Subcortical volume (min-P) | 3e-8 |
| GCST010699_25 | Brain morphology (min-P) | 3e-8 |
EFO canonical traits (from GWAS)
5 canonical traits:
| EFO ID | Trait name |
|---|---|
| EFO:0004348 | hematocrit |
| EFO:0004509 | hemoglobin measurement |
| EFO:0004340 | body mass index |
| EFO:0004346 | neuroimaging measurement |
| EFO:0004840 | cortical thickness |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: yes
ChEMBL targets (1): CHEMBL5724618 (SINGLE PROTEIN)
PharmGKB: 1 entry (CPIC guideline: no)
Binding affinities (BindingDB)
1 measured of 1 human assays (2 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.
| Ligand | Measure | Value |
|---|---|---|
| CHEMBL5653589 | KD | 1440 nM |
ChEMBL bioactivities
2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).
| pChembl | Type | Value | Unit | Molecule |
|---|---|---|---|---|
| 7.09 | Kd | 81.49 | nM | CHEMBL5653589 |
| 7.09 | ED50 | 81.49 | nM | CHEMBL5653589 |
PubChem BioAssay actives
1 with measured affinity, of 8 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.
| Compound | Assay | Type | Value | Unit |
|---|---|---|---|---|
| 4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide | 2148825: Binding affinity to human NASP incubated for 45 mins by Kinobead based pull down assay | kd | 0.0815 | uM |
CTD chemical–gene interactions
84 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol A | decreases expression, affects expression | 4 |
| methylmercuric chloride | decreases expression, increases expression | 3 |
| sodium arsenite | decreases expression, increases expression, increases stability | 3 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, decreases expression | 2 |
| 2,2’,4,4’-tetrabromodiphenyl ether | decreases expression | 2 |
| Resveratrol | increases expression, decreases expression, affects cotreatment | 2 |
| Phenylmercuric Acetate | affects cotreatment, decreases expression | 2 |
| Tretinoin | decreases expression | 2 |
| Valproic Acid | decreases expression, increases expression, increases methylation | 2 |
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | decreases expression | 2 |
| Cyclosporine | decreases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| FR900359 | affects phosphorylation | 1 |
| geldanamycin | increases expression | 1 |
| 2,4,6-tribromophenol | decreases expression | 1 |
| alpha-pinene | affects cotreatment, increases oxidation, increases abundance | 1 |
| geraniol | decreases expression | 1 |
| decabromobiphenyl ether | decreases expression | 1 |
| beta-lapachone | decreases expression | 1 |
| mono-(2-ethylhexyl)phthalate | decreases expression | 1 |
| cobaltous chloride | decreases expression | 1 |
| tetrabromobisphenol A | decreases expression | 1 |
| 2,3-bis(3’-hydroxybenzyl)butyrolactone | affects cotreatment, increases expression | 1 |
| coumarin | decreases phosphorylation | 1 |
| triadimefon | increases expression | 1 |
| methacrylaldehyde | affects cotreatment, increases oxidation, increases abundance | 1 |
| isobutyl alcohol | affects cotreatment, decreases expression, increases abundance | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| K 7174 | decreases expression | 1 |
| erucylphospho-N,N,N-trimethylpropylammonium | decreases expression | 1 |
ChEMBL screening assays
7 unique, capped per target: 7 binding
Representative assays (with source publication via chembl_document):
| Assay ID | Type | Description | Source paper |
|---|---|---|---|
| CHEMBL5651867 | Binding | Binding affinity to human NASP incubated for 45 mins by Kinobead based pull down assay | NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — *ChemMedChem* |
Cellosaurus cell lines
1 cell lines: 1 transformed cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_B3BV | Abcam HEK293T NASP KO | Transformed cell line | Female |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
Predicted chemistry — Sugi Predict
The predicted patent-compound landscape for NASP across ~30M SureChEMBL compounds — explore on Sugi Predict.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.